The table below shows Esperion Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$403.13M
$332.31M
$116.33M
$75.47M
$78.45M
$227.55M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
-
-
-
-
-
-
SG&A
$165.79M
ESPR annual revenue (10-K history)
Esperion Therapeutics, Inc. reported annual revenue of $403.13M for fiscal year 2025. That is up 21.3% from $332.31M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.